[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE69923200D1 - Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe - Google Patents

Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe

Info

Publication number
DE69923200D1
DE69923200D1 DE69923200T DE69923200T DE69923200D1 DE 69923200 D1 DE69923200 D1 DE 69923200D1 DE 69923200 T DE69923200 T DE 69923200T DE 69923200 T DE69923200 T DE 69923200T DE 69923200 D1 DE69923200 D1 DE 69923200D1
Authority
DE
Germany
Prior art keywords
rivastiggins
active ingredients
controlled active
new oral
preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69923200T
Other languages
English (en)
Other versions
DE69923200T2 (de
Inventor
Joerg Ogorka
Oskar Kalb
Rajen Shah
Chandra Khanna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27547321&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69923200(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9821299.6A external-priority patent/GB9821299D0/en
Priority claimed from GBGB9821298.8A external-priority patent/GB9821298D0/en
Priority claimed from GBGB9826654.7A external-priority patent/GB9826654D0/en
Priority claimed from GBGB9827624.9A external-priority patent/GB9827624D0/en
Priority claimed from GBGB9907822.2A external-priority patent/GB9907822D0/en
Priority claimed from GBGB9907823.0A external-priority patent/GB9907823D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE69923200D1 publication Critical patent/DE69923200D1/de
Publication of DE69923200T2 publication Critical patent/DE69923200T2/de
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69923200T 1998-10-01 1999-10-01 Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe Expired - Lifetime DE69923200T2 (de)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
GB9821298 1998-10-01
GBGB9821298.8A GB9821298D0 (en) 1998-10-01 1998-10-01 Organic compoundsq
GB9821299 1998-10-01
GBGB9821299.6A GB9821299D0 (en) 1998-10-01 1998-10-01 Organic compounds
GB9826654 1998-12-03
GBGB9826654.7A GB9826654D0 (en) 1998-12-03 1998-12-03 Organic compounds
GBGB9827624.9A GB9827624D0 (en) 1998-12-16 1998-12-16 Organic compounds
GB9827624 1998-12-16
GB9907822 1999-04-06
GBGB9907823.0A GB9907823D0 (en) 1999-04-06 1999-04-06 Organic compounds
GBGB9907822.2A GB9907822D0 (en) 1999-04-06 1999-04-06 Organic compounds
GB9907823 1999-04-06
PCT/EP1999/007298 WO2000019985A2 (en) 1998-10-01 1999-10-01 New sustained release oral formulations

Publications (2)

Publication Number Publication Date
DE69923200D1 true DE69923200D1 (de) 2005-02-17
DE69923200T2 DE69923200T2 (de) 2005-12-22

Family

ID=27547321

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69923200T Expired - Lifetime DE69923200T2 (de) 1998-10-01 1999-10-01 Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe

Country Status (23)

Country Link
US (5) US20010033866A1 (de)
EP (1) EP1121104B1 (de)
JP (1) JP4012689B2 (de)
KR (1) KR100603900B1 (de)
CN (1) CN1406126A (de)
AT (1) ATE286725T1 (de)
AU (1) AU764866B2 (de)
BR (1) BR9914251A (de)
CA (1) CA2342340C (de)
CZ (1) CZ302888B6 (de)
DE (1) DE69923200T2 (de)
ES (1) ES2237163T3 (de)
HK (1) HK1052473A1 (de)
HU (1) HUP0103883A3 (de)
ID (1) ID27504A (de)
IL (2) IL141762A0 (de)
NO (1) NO331689B1 (de)
NZ (1) NZ510683A (de)
PL (1) PL196945B1 (de)
PT (1) PT1121104E (de)
SK (1) SK285250B6 (de)
TR (1) TR200100931T2 (de)
WO (1) WO2000019985A2 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4012689B2 (ja) * 1998-10-01 2007-11-21 ノバルティス アクチエンゲゼルシャフト 新規徐放性経口製剤
EP1133230A4 (de) * 1998-11-23 2004-05-26 Bonnie M Davis Dosisformulierungen für acetylcholinesterase-inhibitoren
CA2380333A1 (en) * 1999-08-26 2001-03-01 Christian Andina Pharmaceutical formulations
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
CZ299411B6 (cs) * 2000-09-29 2008-07-16 Solvay Pharmaceuticals B. V. Farmaceutický matricový prípravek vytvárející hydrofilní gel a zpusob výroby tohoto prípravku
JP5023412B2 (ja) * 2001-05-09 2012-09-12 吉澤石灰工業株式会社 ホルムアルデヒド廃液の処理剤
JP2005525299A (ja) * 2001-09-14 2005-08-25 スコラー インコーポレイテッド アミノ酸調節性の長期放出投薬形態
PT1424997E (pt) * 2001-09-14 2008-02-28 Scolr Inc Forma de dosagem de libertação prolongada modulada por aminoácidos
KR100453288B1 (ko) * 2002-03-12 2004-10-21 한국화학연구원 약물의 제어 방출을 위한 스퀴즈-유형의 삼투성 약물 전달장치
PT1529116E (pt) * 2002-08-07 2009-09-10 Novartis Ag Métodos para o tratamento da demência com base no genótipo da apo e
AU2003100262B4 (en) * 2003-04-07 2003-09-18 Jurox Pty Ltd Stable carprofen composition
WO2004100929A1 (en) * 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
DK1575565T3 (da) * 2003-08-08 2010-04-12 Biovail Lab Int Srl Tablet med modificeret frigivelse af bupropion-hydrochlorid
US20100129310A1 (en) * 2004-08-09 2010-05-27 Pavak Rajnikanth Mehta Stabilized desloratadine composition
ES2403069T3 (es) * 2005-02-22 2013-05-13 Sun Pharma Advanced Research Company Ltd Composición oral de liberación controlada que contiene levetiracetam
EP1879583A2 (de) * 2005-05-03 2008-01-23 Mutual Pharmaceutical Company, Inc. Chininformulierungen
WO2007026864A1 (ja) * 2005-09-01 2007-03-08 Eisai R & D Management Co., Ltd. 崩壊性の改善された医薬組成物の製造方法
GB0525461D0 (en) * 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
GB0606562D0 (en) * 2006-03-31 2006-05-10 Novartis Ag Organic compounds
JP5230613B2 (ja) 2006-05-23 2013-07-10 テラコス・インコーポレイテッド グルコース輸送体阻害剤およびその使用方法
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US7838498B2 (en) 2007-04-02 2010-11-23 Theracos, Inc. Benzylic glycoside derivatives and methods of use
ITMI20071502A1 (it) * 2007-07-25 2009-01-26 Archimica Srl Procedimento per la preparazione di formulazioni solide a rilascio controllato contenenti oxcarbazepina e formulazioni ottenibili con tale procedimento
WO2009022345A1 (en) * 2007-08-14 2009-02-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Phenyl carbamates for the treatment of multiple sclerosis
UA99924C2 (en) 2007-08-23 2012-10-25 Теракос, Инк. Benzylbenzol derivatives and using thereof
WO2009042625A1 (en) * 2007-09-25 2009-04-02 Idexx Laboratories, Inc. Pharmaceutical compositions for administering oligonucleotides
US20110201597A1 (en) 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
AR072511A1 (es) 2008-07-15 2010-09-01 Theracos Inc Derivados deuterados de bencilbenceno y metodos de uso. composicion farmaceutica.
PT2324002T (pt) 2008-08-22 2016-11-09 Theracos Sub Llc Processos para a preparação de inibidores de sglt2
EP2379561B1 (de) 2008-11-25 2015-11-04 University Of Rochester Mlk-inhibitoren und anwendungsverfahren
MX345236B (es) * 2009-09-18 2017-01-23 Chase Pharmaceuticals Corp Metodo y composicion para tratar la demencia de tipo alzheimer.
US20110150986A1 (en) * 2009-12-18 2011-06-23 Kristin Arnold Quinine formulations, method of making, and metho of use thereof
CN101797236B (zh) * 2010-03-23 2012-05-23 西南大学 重酒石酸卡巴拉汀口腔崩解片及其制备方法
CN103153994B (zh) 2010-05-24 2016-02-10 罗切斯特大学 双环杂芳基激酶抑制剂及使用方法
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
ES2716865T3 (es) 2011-02-18 2019-06-17 Scripps Research Inst Diferenciación dirigida de células precursoras de oligodendrocitos a un destino celular mielinizante
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
MX2013012918A (es) * 2011-05-06 2013-11-21 Glaxosmithkline Llc Formulaciones de liberacion sostenida de paracetamol.
SG10201606751XA (en) * 2011-05-13 2016-10-28 Eb Ip Hybritabs B V Drug Delivery System
US8524664B2 (en) 2011-06-02 2013-09-03 Colorado Seminary, Which owns and Operates The Univeristy of Denver Methods of treating overproduction of cortisol using ACTH antagonist peptides
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
IN2014DN04226A (de) 2011-11-14 2015-05-22 Gen Hospital Corp
JP2015531346A (ja) 2012-09-05 2015-11-02 チェイス・ファーマスーティカルズ・コーポレーション 抗コリン作用性神経保護組成物及び方法
CN104884059B (zh) 2012-11-30 2018-08-10 罗切斯特大学 用于hiv/aids治疗的混合谱系激酶抑制剂
JPWO2014098176A1 (ja) 2012-12-21 2017-01-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
CN105264380B (zh) 2013-05-14 2017-09-05 卫材R&D管理有限公司 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
WO2015022418A1 (en) 2013-08-16 2015-02-19 Takeda Gmbh Treatment of cognitive impairment with pde4 inhibitor
WO2015136446A1 (en) 2014-03-11 2015-09-17 Nestec S.A. Methods for selecting antidepressant drug therapy to treat depression
CN103877063A (zh) * 2014-03-24 2014-06-25 张绪伟 一种重酒石酸卡巴拉汀胶囊及其制备方法
HRP20221047T1 (hr) 2014-08-28 2022-11-11 Eisai R&D Management Co., Ltd. Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
HUE064614T2 (hu) 2015-02-25 2024-04-28 Eisai R&D Man Co Ltd Eljárás egy kinolin-származék keserû ízének elnyomására
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
KR101990951B1 (ko) * 2015-04-27 2019-06-20 주식회사 네비팜 리바스티그민 함유 서방출 의약조성물
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
KR20190021180A (ko) * 2017-08-22 2019-03-05 아주대학교산학협력단 퇴행성 신경질환 치료용 복합 제형 조성물
KR20190036370A (ko) 2017-09-27 2019-04-04 서원대학교산학협력단 약물의 서방성 제형을 위한 약물전달체
CA3123928C (en) 2018-07-30 2023-11-14 Biothea Pharma, Inc. Crystalline epinephrine malonate salt
CN112546037A (zh) * 2020-12-08 2021-03-26 苏州大学 卡巴拉汀在制备抗辐射药中的应用
CN113398273B (zh) * 2021-05-14 2022-07-19 广西壮族自治区中国科学院广西植物研究所 木聚糖衍生物作为亲水性缓释材料在制备药物缓释片中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4014335A (en) * 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
USRE34990E (en) * 1986-08-07 1995-07-04 Ciba-Geigy Corporation Oral therapeutic system having systemic action
NL195004C (nl) 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
DE3805744C2 (de) * 1987-03-04 1999-09-23 Novartis Ag Phenylcarbamate zur Hemmung der Acetylcholinesterase
US5472710A (en) * 1988-04-16 1995-12-05 Schwarz Pharma Ag Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture
DE3922167A1 (de) * 1988-04-16 1991-01-17 Sanol Arznei Schwarz Gmbh Oral zu verabreichende diltiazemhydrochlorid enthaltende pharmazeutische zubereitung zur einmal taeglichen applikation und verfahren zu deren herstellung
US5262173A (en) * 1992-03-02 1993-11-16 American Cyanamid Company Pulsatile once-a-day delivery systems for minocycline
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
PT621032E (pt) * 1993-04-23 2001-01-31 Novartis Ag Dispositivo de distribuicao de libertacao controlada de farmaco
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
GB9701695D0 (en) 1997-01-28 1997-03-19 De Beers Ind Diamond Insert for an abrasive tool
DE19707655A1 (de) * 1997-02-26 1998-08-27 Hoechst Ag Kombinationspräparat zur Anwendung bei Demenz
WO1998053802A1 (en) * 1997-05-30 1998-12-03 Laboratorios Phoenix U.S.A., Inc. Multi-layered osmotic device
GB9800526D0 (en) * 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
JP4012689B2 (ja) 1998-10-01 2007-11-21 ノバルティス アクチエンゲゼルシャフト 新規徐放性経口製剤
US6534541B1 (en) 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders

Also Published As

Publication number Publication date
NO20011471D0 (no) 2001-03-22
JP4012689B2 (ja) 2007-11-21
CN1406126A (zh) 2003-03-26
CA2342340C (en) 2006-08-29
US20070053982A1 (en) 2007-03-08
JP2002526402A (ja) 2002-08-20
KR100603900B1 (ko) 2006-07-25
US6565883B2 (en) 2003-05-20
AU6332199A (en) 2000-04-26
CZ302888B6 (cs) 2012-01-11
SK285250B6 (sk) 2006-09-07
SK4392001A3 (en) 2002-07-02
BR9914251A (pt) 2001-06-19
NO331689B1 (no) 2012-02-27
DE69923200T2 (de) 2005-12-22
ID27504A (id) 2001-04-12
US20010033866A1 (en) 2001-10-25
WO2000019985A3 (en) 2000-07-20
ATE286725T1 (de) 2005-01-15
NO20011471L (no) 2001-03-22
CA2342340A1 (en) 2000-04-13
US20030039692A1 (en) 2003-02-27
EP1121104B1 (de) 2005-01-12
AU764866B2 (en) 2003-09-04
WO2000019985A2 (en) 2000-04-13
TR200100931T2 (tr) 2001-10-22
ES2237163T3 (es) 2005-07-16
US20050175706A1 (en) 2005-08-11
NZ510683A (en) 2003-09-26
EP1121104A2 (de) 2001-08-08
PT1121104E (pt) 2005-05-31
CZ20011155A3 (cs) 2001-08-15
HUP0103883A2 (hu) 2002-05-29
KR20010073168A (ko) 2001-07-31
PL348734A1 (en) 2002-06-03
US20030203025A1 (en) 2003-10-30
PL196945B1 (pl) 2008-02-29
IL141762A0 (en) 2002-03-10
IL141762A (en) 2010-06-30
HUP0103883A3 (en) 2002-11-28
HK1052473A1 (zh) 2003-09-19

Similar Documents

Publication Publication Date Title
DE69923200D1 (de) Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
FI973828A0 (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
TR199802423T2 (xx) Konsantre antikor terkibi.
DK196189D0 (da) Oralt osmotisk dispenseringssystem indeholdende et farmakologisk aktivt stof
DK1035834T3 (da) Osmotisk doseringsform omfattende en første og anden coating
DK0572942T3 (da) Orale farmaceutiske præparater til specifik frigivelse i kolon
TR199501137A2 (tr) Terapötik olarak aktif bilesenler
ATE260090T1 (de) Neue suppositoriumsform mit säureempfindliche wirkstoffe
TR200100366T2 (tr) Aktif madde dağıtmaya mahsus bileşikler ve bileşimler.
ES2133785T3 (es) Inhibidores de metaloproteinasas.
DE69931925D1 (de) 2-chinolonen enthaltende arzneimittel
DK0994710T4 (da) Farmaceutiske præparater til oral indgivelse omfattende en benzylhydrylpiperazin og en cyclodextrin
DK1112060T3 (da) Doseringsform anvendende flydende formulering
PT837684E (pt) Composicoes farmaceuticas a base de um sal de diclofenac e de tiocolchicosido
DE69927374D1 (de) Entzündungshemmende pharmazeutische formulierungen
ATE353224T1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
TR200200683T2 (tr) Oral kontrollü salıverme formülasyonları.
AR012638A1 (es) Uso de pregnan-3-ol-20-onas para la manufactura de un medicamento util para proveer una terapia progestacional
DK0742716T3 (da) Farmaceutisk sammensætning til systemisk transdermal indgivelse med det aktive middel morphin-6-glucuronid
BR9710629A (pt) Composi-Æo farmac-utica processo para sua prepara-Æo composto para utiliza-Æo como agente terap-utico e utiliza-Æo e utiliza-Æo de um composto
HUP9701598A2 (hu) Gyógyszerkészítmény
RS49796B (sr) UPOTREBA SOLI 3α, 7α-DIHIDROKSI-12-KETO-5β-HOLANSKE KISELINE KAO AKTIVNE SUPSTANCE ZA IZRADU LEKOVA ZA LEČENJE DIJABETESA
EE9700021A (et) Fibriinile mõju avaldav monoklooniline antikeha kasutamiseks tromboosivastases ravis, farmatseutilised kompositsioonid ja ravimaine

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN